Pierre Jean-Marie Raboisson,Herman Augustinus De Kock,David Craig McGowan,Lili Hu,Abdellah Tahri,Sandrine Marie Helene Vendeville,Wim Van De Vreken
申请号：
US14135826
公开号：
US09365582B2
申请日:
2013.12.20
申请国别(地区):
US
年份:
2016
代理人:
摘要：
Inhibitors of HCV replication of formula (I)and the salts and stereoisomers thereof, whereineach dashed line (represented by - - - - -) represents an optional double bond；X is N, CH and where X bears a double bond it is C；R1 is —OR7, —NH—SO2R8；R2 is hydrogen, and where X is C or CH, R2 may also be C1-6alkyl；R3 is hydrogen, C1-6alkyl, C1-6alkoxyC1-6alkyl, C3-7cycloalkyl；n is 3, 4, 5, or 6；R4 is C1-6alkyl or C3-7cycloalkyl；R5 is hydrogen, halo, C1-6alkyl, hydroxy, C1-6alkoxy, polyhaloC1-6alkyl；R6 is hydrogen, C1-6alkoxy, mono- or diC1-6alkylamino； orR5 and R6 may form a 5- or 6-membered unsaturated or partially unsaturated ring, optionally comprising one or two selected from O, N and S；R7 is hydrogen； C3-7cycloalkyl optionally substituted with C1-6alkyl； or C1-6alkyl optionally substituted with C3-7cycloalkyl；R8 is C3-7cycloalkyl optionally substituted with C1-6alkyl； C1-6alkyl optionally substituted with C3-7cycloalkyl； or —NR8aR8b； R8a and R8b are C1-6alkyl, or both may form a 5- or 6-membered saturated heterocyclic ring；pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I).
